@kenolivelab : Stunning interim clinical trial data from Revolution Medicines... PFS = 8.1 mo in 2nd line KRAS G12-mutant metastatic #PDAC. OS not yet reached, but already more than a year! Benchmark PFS for this group is 2-3.5 months, behnchmark OS is 6.1-6.9. 1/ • TwiCopy

KenOliveLab

@kenolivelab

+ Follow

Asc Prof. of Medicine, Columbia University, views own.
Pancreatic cancer, translational therapeutics, metabolism, systems, paracrine interactions. It all fits.

ID: 1030276342976274432

linkhttps://www.cancer.columbia.edu/profile/kenneth-p-olive-phd calendar_today17-08-2018 02:13:16

2,2K Tweet

3,3K Followers

407 Following

KenOliveLab

@kenolivelab

2 months ago

Stunning interim clinical trial data from Revolution Medicines... PFS = 8.1 mo in 2nd line KRAS G12-mutant metastatic #PDAC. OS not yet reached, but already more than a year! Benchmark PFS for this group is 2-3.5 months, behnchmark OS is 6.1-6.9. 1/